Carboplatin Injection IP 450mg
CARBOLIEVA 450 MG (Carboplatin Injection IP 450 mg) is a prescription anticancer medicine containing Carboplatin 450 mg, a platinum-based chemotherapy agent used in the treatment of various cancers. Carboplatin belongs to the class of Platinum Coordination Compounds, which work by damaging the DNA of cancer cells and preventing their growth, multiplication, and spread.
Carboplatin is widely used in oncology because of its proven effectiveness and comparatively favorable safety profile when compared to some other platinum-based chemotherapy agents. It interferes with cancer cell DNA by forming cross-links that prevent proper DNA replication and transcription, ultimately leading to cancer cell death.
CARBOLIEVA 450 MG is commonly prescribed as a single-agent therapy or as part of combination chemotherapy regimens for the treatment of ovarian cancer, lung cancer, head and neck cancer, breast cancer, and several other solid tumors.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
CARBOLIEVA 450 MG is commonly used for:
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Head and Neck Cancer
Breast Cancer
Cervical Cancer
Endometrial Cancer
Germ Cell Tumors
Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, CARBOLIEVA 450 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Carboplatin therapy require routine monitoring of blood counts, kidney function, liver function, and overall health status to ensure optimal treatment outcomes.
Due to its broad clinical utility and established efficacy, CARBOLIEVA 450 MG remains an important medicine in modern oncology care.
View Details
Carboplatin Injection IP 150mg
CARBOLIEVA 150 MG (Carboplatin Injection IP 150 mg) is a prescription anticancer medicine containing Carboplatin 150 mg, a platinum-based chemotherapy agent widely used in the treatment of various solid tumors. Carboplatin belongs to the class of Platinum Coordination Compounds, which work by interfering with the DNA of cancer cells, preventing their growth, multiplication, and spread.
Carboplatin is a well-established chemotherapy medicine used in modern oncology for its effectiveness against multiple cancer types and its predictable safety profile. The medicine forms cross-links within cancer cell DNA, disrupting DNA replication and cellular function, ultimately leading to cancer cell death.
CARBOLIEVA 150 MG is commonly prescribed either as a single-agent therapy or as part of combination chemotherapy regimens for cancers such as ovarian cancer, lung cancer, breast cancer, cervical cancer, and other advanced solid tumors.
The 150 mg strength provides flexibility in chemotherapy dosing and allows oncologists to tailor treatment according to the patient’s body surface area (BSA), kidney function, and treatment protocol.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
CARBOLIEVA 150 MG is commonly used for:
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Breast Cancer
Cervical Cancer
Head and Neck Cancer
Endometrial Cancer
Germ Cell Tumors
Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, CARBOLIEVA 150 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Carboplatin therapy require routine monitoring of blood counts, kidney function, liver function, and overall health status to support safe and effective treatment.
Due to its established efficacy across multiple cancer indications, CARBOLIEVA 150 MG remains an important medicine in modern cancer care.
View Details
Paclitaxel (Protein Bound Particles) for Injection Suspension 100 MG
NAB-PACLIEVA 100 MG (Paclitaxel Protein-Bound Particles for Injection Suspension 100 mg) is a prescription anticancer medicine containing Paclitaxel 100 mg formulated as albumin-bound (protein-bound) nanoparticles for intravenous administration. This advanced formulation is designed to improve the delivery of Paclitaxel to tumor tissues while eliminating the need for certain solvent-based excipients used in conventional paclitaxel formulations.
Paclitaxel belongs to a class of medicines known as Taxane Antineoplastic Agents, which work by interfering with the normal function of microtubules inside cancer cells. By stabilizing microtubules and preventing their breakdown, Paclitaxel inhibits cell division and ultimately leads to cancer cell death.
NAB-PACLIEVA 100 MG is widely used in the treatment of several cancers, including breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. It may be administered alone or in combination with other anticancer medicines depending on the treatment protocol and patient condition.
The albumin-bound technology enhances drug transport and allows effective chemotherapy delivery without the need for certain solvent-related premedications commonly required with conventional Paclitaxel formulations.
NAB-PACLIEVA 100 MG is commonly prescribed for:
Metastatic Breast Cancer
Advanced Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Pancreatic Cancer
Locally Advanced Pancreatic Cancer
Combination Chemotherapy Programs
Oncology Treatment Protocols
Advanced Solid Tumors
Manufactured according to stringent pharmaceutical quality standards, NAB-PACLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving treatment require regular monitoring of blood counts, liver function, and overall health status throughout therapy.
Due to its proven efficacy and innovative formulation, NAB-PACLIEVA 100 MG remains an important option in modern oncology treatment.
View Details
Fulvestrant Injection 250 MG
FALSOLIEVA 250 MG (Fulvestrant Injection 250 mg) is a prescription anticancer medicine containing Fulvestrant 250 mg, a hormonal therapy used primarily in the treatment of hormone receptor-positive (HR-positive) breast cancer in postmenopausal women. Fulvestrant belongs to a class of medicines known as Selective Estrogen Receptor Degraders (SERDs), which work by blocking and reducing estrogen receptors on cancer cells.
Many breast cancer cells depend on estrogen to grow and multiply. Fulvestrant binds to estrogen receptors and accelerates their degradation, reducing the ability of cancer cells to receive estrogen signals. This action helps slow or stop the growth of hormone-sensitive breast cancer cells.
FALSOLIEVA 250 MG is commonly used in the treatment of advanced breast cancer, locally advanced breast cancer, and metastatic breast cancer. It may be prescribed alone or in combination with targeted therapies, depending on the patient's clinical condition and treatment plan.
The medicine is administered as an intramuscular injection under the supervision of qualified healthcare professionals experienced in oncology treatment.
FALSOLIEVA 250 MG is commonly prescribed for:
Hormone Receptor-Positive (HR-Positive) Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Estrogen Receptor-Positive (ER-Positive) Breast Cancer
Endocrine Therapy for Breast Cancer
Combination Targeted Therapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, FALSOLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Fulvestrant therapy require regular medical evaluations and monitoring to assess treatment response and overall health status.
Due to its proven effectiveness in hormone-sensitive breast cancer, FALSOLIEVA 250 MG remains an important component of modern breast cancer management.
View Details
Docetaxel Injection IP 120 MG
DOCELIEVA 120 MG (Docetaxel Injection IP 120 mg) is a prescription anticancer medicine containing Docetaxel 120 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Docetaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth.
Docetaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This disruption inhibits cancer cell replication and ultimately leads to cancer cell death. Due to its proven efficacy, Docetaxel is an important component of modern oncology treatment protocols.
DOCELIEVA 120 MG is commonly prescribed for the treatment of breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric cancer, and head and neck cancers. It may be administered as a single-agent therapy or in combination with other anticancer medicines depending on the treatment plan.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
DOCELIEVA 120 MG is commonly used for:
Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Prostate Cancer
Gastric Cancer
Head and Neck Cancer
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, DOCELIEVA 120 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Docetaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and proven effectiveness, DOCELIEVA 120 MG remains a key medicine in modern cancer management.
View Details
Docetaxel Injection IP 80 MG
DOCELIEVA 80 MG (Docetaxel Injection IP 80 mg) is a prescription anticancer medicine containing Docetaxel 80 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Docetaxel is widely used in the treatment of various cancers by disrupting cancer cell division and slowing tumor growth.
Docetaxel works by stabilizing microtubules inside cancer cells, preventing their normal breakdown during mitosis (cell division). This action inhibits cancer cell replication and ultimately leads to cancer cell death. Due to its established efficacy, Docetaxel is an important component of many oncology treatment protocols worldwide.
DOCELIEVA 80 MG is commonly prescribed for the treatment of breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric cancer, and head and neck cancers. It may be administered as a single-agent therapy or in combination with other anticancer medicines depending on the patient's treatment plan.
The 80 mg strength offers flexibility for individualized dosing based on body surface area (BSA), treatment protocols, and clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
DOCELIEVA 80 MG is commonly used for:
Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Prostate Cancer
Gastric Cancer
Head and Neck Cancer
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, DOCELIEVA 80 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Docetaxel therapy require routine monitoring of blood counts, liver function, and overall clinical status throughout treatment.
Due to its broad clinical applications and proven effectiveness, DOCELIEVA 80 MG remains a trusted medicine in modern cancer management.
View Details
Docetaxel Injection IP 20mg
DOCELIEVA 20 MG (Docetaxel Injection IP 20 mg) is a prescription anticancer medicine containing Docetaxel 20 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Docetaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth and spread.
Docetaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately leads to cancer cell death. Due to its proven effectiveness, Docetaxel is an important component of modern oncology treatment protocols.
DOCELIEVA 20 MG is commonly prescribed for the treatment of breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric cancer, and head and neck cancers. It may be administered alone or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The 20 mg strength provides flexibility for individualized dosing, dose adjustments, and combination chemotherapy regimens based on patient-specific clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
DOCELIEVA 20 MG is commonly used for:
Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Prostate Cancer
Gastric Cancer
Head and Neck Cancer
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, DOCELIEVA 20 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Docetaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and established efficacy, DOCELIEVA 20 MG remains an important medicine in modern cancer care.
View Details
Paclitaxel Injection 300mg
PACLIEVA 300 MG (Paclitaxel Injection 300 mg) is a prescription anticancer medicine containing Paclitaxel 300 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This disruption of cellular replication inhibits cancer cell growth and ultimately leads to cancer cell death. Due to its proven efficacy, Paclitaxel is an important component of many oncology treatment protocols worldwide.
PACLIEVA 300 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used alone or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 300 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 300 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require routine monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and established effectiveness, PACLIEVA 300 MG remains an important medicine in modern cancer care.
View Details
Paclitaxel Injection 260mg
PACLIEVA 260 MG (Paclitaxel Injection 260 mg) is a prescription anticancer medicine containing Paclitaxel 260 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately leads to cancer cell death. Due to its established efficacy, Paclitaxel has become an important component of modern oncology treatment protocols worldwide.
PACLIEVA 260 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used alone or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 260 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 260 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and proven effectiveness, PACLIEVA 260 MG remains an important medicine in modern cancer management.
View Details
Paclitaxel Injection 100 mg
PACLIEVA 100 MG (Paclitaxel Injection 100 mg) is a prescription anticancer medicine containing Paclitaxel 100 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by inhibiting cancer cell division and slowing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately causes cancer cell death. Due to its established efficacy, Paclitaxel has become an important component of modern oncology treatment protocols worldwide.
PACLIEVA 100 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used as a single-agent therapy or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The 100 mg strength provides flexibility for individualized dosing and combination chemotherapy regimens based on patient-specific clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 100 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and proven effectiveness, PACLIEVA 100 MG remains an important medicine in modern cancer care.
View Details
Paclitaxel Injection 30 mg
PACLIEVA 30 MG (Paclitaxel Injection 30 mg) is a prescription anticancer medicine containing Paclitaxel 30 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately causes cancer cell death. Due to its proven efficacy, Paclitaxel is a key component of many oncology treatment protocols worldwide.
PACLIEVA 30 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used alone or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The 30 mg strength provides flexibility for individualized dosing, dose adjustments, and combination chemotherapy regimens based on patient-specific clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 30 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 30 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require routine monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and established effectiveness, PACLIEVA 30 MG remains an important medicine in modern cancer care.
View Details
Regorafenib Tablet BP 40mg
REGOLIEVA 40 MG (Regorafenib Tablets BP 40 mg) is a prescription anticancer medicine containing Regorafenib 40 mg, an oral multi-kinase inhibitor used in the treatment of certain advanced cancers. Regorafenib belongs to a class of medicines known as Targeted Therapy Agents, which work by blocking multiple protein kinases involved in tumor growth, cancer progression, and blood vessel formation.
Regorafenib inhibits various signaling pathways responsible for cancer cell proliferation and angiogenesis (formation of new blood vessels that supply tumors). By targeting these pathways, the medicine helps slow tumor growth and disease progression.
REGOLIEVA 40 MG is commonly prescribed for the treatment of metastatic colorectal cancer (mCRC), gastrointestinal stromal tumors (GIST) after failure of prior therapies, and hepatocellular carcinoma (HCC) in selected patients. It may also be used according to the oncologist's recommendation as part of specific cancer treatment protocols.
The medicine is administered orally and should be taken exactly as prescribed by a qualified healthcare professional experienced in oncology treatment.
REGOLIEVA 40 MG is commonly used for:
Metastatic Colorectal Cancer (mCRC)
Gastrointestinal Stromal Tumor (GIST)
Hepatocellular Carcinoma (HCC)
Advanced Solid Tumors
Targeted Cancer Therapy
Oncology Treatment Programs
Tumor Growth Control
Cancer Progression Management
Manufactured according to stringent pharmaceutical quality standards, REGOLIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Regorafenib therapy require regular monitoring of liver function, blood pressure, and overall health status throughout treatment.
Due to its targeted mechanism of action and proven clinical efficacy, REGOLIEVA 40 MG remains an important option in modern oncology care.
View Details
